|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15571558155915601561156215631564156515661567...15771578» |
- tandutinib (MLN518) / Takeda
Trial completion: Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma (clinicaltrials.gov) - Oct 6, 2013
P1/2, N=85, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed
- ||| imatinib / Generic mfg.
Enrollment closed, Stroma: Five Year Adjuvant Imatinib Mesylate (Gleevec (clinicaltrials.gov) - Oct 5, 2013
P2, N=91, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial initiation date: Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers (clinicaltrials.gov) - Oct 3, 2013
P=N/A, N=200, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting Initiation date: Jul 2013 --> Oct 2013
- BI2536 / Boehringer Ingelheim
Trial completion, Metastases: BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors (clinicaltrials.gov) - Oct 3, 2013
P2, N=76, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Initiation date: Jul 2013 --> Oct 2013 Active, not recruiting --> Completed
- Enrollment open: DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With High-risk Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 29, 2013
P1/2, N=30, Recruiting, Sponsor: Affiliated Hospital to Academy of Military Medical Sciences
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- Enrollment change, Surgery: Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass (clinicaltrials.gov) - Sep 29, 2013
P=N/A, N=30, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting N=22 --> 30
- iC9-GD2-CAR-VZV-CTLs / Baylor College of Medicine
New P1 trial, Metastases: VEGAS: iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma (clinicaltrials.gov) - Sep 29, 2013
P1, N=26, Not yet recruiting, Sponsor: Baylor College of Medicine
- Enrollment closed, Surgery: Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass (clinicaltrials.gov) - Sep 29, 2013
P=N/A, N=30, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=22 --> 30 Recruiting --> Active, not recruiting
- Votrient (pazopanib) / Novartis, BeiGene
Trial completion: Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment (clinicaltrials.gov) - Sep 26, 2013
P1, N=55, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment change, IO biomarker: Predictive Study of Radiation Induced Sarcoma (clinicaltrials.gov) - Sep 24, 2013
P=N/A, N=360, Recruiting, Sponsor: Centre Georges Francois Leclerc
Active, not recruiting --> Completed N=240 --> 360
- Trial termination, Surgery: Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma (clinicaltrials.gov) - Sep 22, 2013
P2, N=7, Terminated, Sponsor: Children's Oncology Group
N=240 --> 360 Completed --> Terminated; Due to poor accrual
- PSMA ADC / Lantheus
Enrollment open: BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) (clinicaltrials.gov) - Sep 22, 2013
P2, N=25, Recruiting, Sponsor: Heinrich Elinzano, MD
Completed --> Terminated; Due to poor accrual Not yet recruiting --> Recruiting
- Trial completion: Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases (clinicaltrials.gov) - Sep 22, 2013
P=N/A, N=20, Completed, Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Not yet recruiting --> Recruiting Recruiting --> Completed
- BI2536 / Boehringer Ingelheim
Enrollment change, Metastases: BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors (clinicaltrials.gov) - Sep 19, 2013
P2, N=76, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Completed N=185 --> 76
- Biomarker, Trial completion: Retinoblastoma Biomarker Study (clinicaltrials.gov) - Sep 18, 2013
P=N/A, N=700, Completed, Sponsor: National Cancer Institute (NCI)
N=185 --> 76 Active, not recruiting --> Completed
- |||| Votrient (pazopanib) / Novartis, BeiGene
Trial completion: Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 18, 2013
P2, N=148, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
New P2 trial: Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors (clinicaltrials.gov) - Sep 17, 2013
P2, N=47, Recruiting, Sponsor: St. Jude Children's Research Hospital
- adavosertib (AZD1775) / AstraZeneca
Enrollment open: Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (clinicaltrials.gov) - Sep 15, 2013
P1, N=65, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- luminespib (AUY922) / Ligand, sunitinib / Generic mfg.
Trial initiation date, Stroma, Metastases: A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients (clinicaltrials.gov) - Sep 13, 2013
P2, N=25, Recruiting, Sponsor: National Health Research Institutes, Taiwan
Not yet recruiting --> Recruiting Initiation date: Jul 2011 --> Oct 2011
- luminespib (AUY922) / Ligand, sunitinib / Generic mfg.
Enrollment open, Stroma, Metastases: A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients (clinicaltrials.gov) - Sep 13, 2013
P2, N=25, Recruiting, Sponsor: National Health Research Institutes, Taiwan
Initiation date: Jul 2011 --> Oct 2011 Not yet recruiting --> Recruiting
- | robatumumab (SCH 717454) / Merck (MSD)
Trial termination: A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720) (clinicaltrials.gov) - Sep 12, 2013
P2, N=219, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; The study was prematurely terminated for strategic reasons, not for a safety concern.
- | Trial completion: Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 12, 2013
P3, N=340, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Terminated; The study was prematurely terminated for strategic reasons, not for a safety concern. Active, not recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD)
Enrollment change, Metastases: Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 10, 2013
P2, N=16, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=45 --> 16
- Zolinza (vorinostat) / Merck (MSD)
Trial completion, Metastases: Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Sep 10, 2013
P2, N=16, Completed, Sponsor: National Cancer Institute (NCI)
N=45 --> 16 Active, not recruiting --> Completed
- | sunitinib / Generic mfg.
Trial completion, Stroma: SU011248 in Treating Patients With Malignant Gastrointestinal Stromal Tumor (clinicaltrials.gov) - Sep 4, 2013
P3, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Omblastys (131I-omburtamab) - Y / mAbs Therap
Enrollment change, Metastases: Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer (clinicaltrials.gov) - Sep 3, 2013
P1, N=120, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed N=80 --> 120
- Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
New P2 trial, Metastases: Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer (clinicaltrials.gov) - Sep 3, 2013
P2, N=36, Recruiting, Sponsor: National Cancer Institute (NCI)
- || Trial initiation date: US-nCLE: Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract (clinicaltrials.gov) - Sep 2, 2013
P=N/A, N=70, Not yet recruiting, Sponsor: Mauna Kea Technologies
N=80 --> 120 Initiation date: Feb 2013 --> Sep 2013
- |||||||||| Koselugo (selumetinib) / Merck (MSD), AstraZeneca
New P3 trial, Combination therapy, Metastases: Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (clinicaltrials.gov) - Aug 29, 2013
P3, N=4225, Recruiting, Sponsor: AstraZeneca
- | Votrient (pazopanib) / Novartis, BeiGene, Avastin (bevacizumab) / Roche
New P2 trial: Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab (clinicaltrials.gov) - Aug 27, 2013
P2, N=66, Recruiting, Sponsor: M.D. Anderson Cancer Center
- Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Enrollment open, P1 data: A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma (clinicaltrials.gov) - Aug 26, 2013
P1, N=20, Recruiting, Sponsor: NPM Pharma Inc.
Initiation date: Feb 2013 --> Sep 2013 Not yet recruiting --> Recruiting
- temozolomide / Generic mfg.
Enrollment closed: MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Aug 26, 2013
P2, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- taladegib (ENV 101) / Endeavor BioMed
Trial withdrawal: A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma (clinicaltrials.gov) - Aug 25, 2013
P1, N=0, Withdrawn, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial termination, Metastases: Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 25, 2013
P2b, N=370, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting --> Withdrawn Suspended --> Terminated; Results of step1: none of the experimental arms fulfills expectations and the study will not continue as a phase III.
- taladegib (ENV 101) / Endeavor BioMed
Enrollment change: A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma (clinicaltrials.gov) - Aug 25, 2013
P1, N=0, Withdrawn, Sponsor: Eli Lilly and Company
Suspended --> Terminated; Results of step1: none of the experimental arms fulfills expectations and the study will not continue as a phase III. N=40 --> 0
- Trial completion: Radiation Therapy in Treating Patients With Aggressive Fibromatoses (clinicaltrials.gov) - Aug 25, 2013
P2, N=44, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=40 --> 0 Active, not recruiting --> Completed
- methotrexate IV / Generic mfg.
Enrollment open, HEOR, Cost effectiveness: Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma (clinicaltrials.gov) - Aug 22, 2013
P3, N=12, Recruiting, Sponsor: The Hospital for Sick Children
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment open: Proton Radiation for Chordomas and Chondrosarcomas (clinicaltrials.gov) - Aug 19, 2013
P1/2, N=50, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- Enrollment closed: Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS) (clinicaltrials.gov) - Aug 19, 2013
P2, N=20, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial initiation date: ANGIHE: Identification, Molecular Epidemiology Angiosarcoma of the Liver France (clinicaltrials.gov) - Aug 18, 2013
P=N/A, N=30, Recruiting, Sponsor: Centre Oscar Lambret
Recruiting --> Active, not recruiting Initiation date: Feb 2013 --> Jun 2013
- Enrollment open: ANGIHE: Identification, Molecular Epidemiology Angiosarcoma of the Liver France (clinicaltrials.gov) - Aug 18, 2013
P=N/A, N=30, Recruiting, Sponsor: Centre Oscar Lambret
Initiation date: Feb 2013 --> Jun 2013 Not yet recruiting --> Recruiting
- | imatinib / Generic mfg.
Enrollment change, Stroma: Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST) (clinicaltrials.gov) - Aug 17, 2013
P2, N=30, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=39 --> 30
- | Votrient (pazopanib) / Novartis
Trial suspension, Combination therapy: Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 15, 2013
P2, N=80, Suspended, Sponsor: OHSU Knight Cancer Institute
N=39 --> 30 Recruiting --> Suspended
- ||| Stivarga (regorafenib) / Bayer
Trial initiation date, Metastases: REGO-SARC: Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 15, 2013
P2, N=192, Recruiting, Sponsor: Centre Oscar Lambret
Recruiting --> Suspended Initiation date: Mar 2013 --> Jun 2013
- ||| aldoxorubicin (INNO-206) / ImmunityBio
Enrollment closed, Metastases: Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 15, 2013
P2, N=105, Active, not recruiting, Sponsor: CytRx
Initiation date: Mar 2013 --> Jun 2013 Recruiting --> Active, not recruiting
- ||| Rintega (rindopepimut) / Celldex
Enrollment change: A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma (clinicaltrials.gov) - Aug 14, 2013
P2, N=168, Recruiting, Sponsor: Celldex Therapeutics
Recruiting --> Active, not recruiting N=95 --> 168
- temozolomide / Generic mfg.
Enrollment open: GCC 1224: Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Aug 13, 2013
P2, N=47, Recruiting, Sponsor: University of Maryland
N=95 --> 168 Not yet recruiting --> Recruiting
- Recentin (cediranib) / AstraZeneca
Trial completion: AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Aug 13, 2013
P2, N=31, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Recruiting --> Completed
- Enrollment change: CoRDS: Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (clinicaltrials.gov) - Aug 12, 2013
P=N/A, N=10000, Recruiting, Sponsor: Sanford Health
Recruiting --> Completed N=1000 --> 10000
- adavosertib (AZD1775) / AstraZeneca
New P1 trial: Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (clinicaltrials.gov) - Aug 12, 2013
P1, N=65, Recruiting, Sponsor: National Cancer Institute (NCI)